Catalyst Pharmaceuticals, Inc. (CPRX)
Automate Your Wheel Strategy on CPRX
With Tiblio's Option Bot, you can configure your own wheel strategy including CPRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CPRX
- Rev/Share 4.5718
- Book/Share 7.0073
- PB 2.8085
- Debt/Equity 0.003
- CurrentRatio 6.7141
- ROIC 0.2174
- MktCap 2408654880.0
- FreeCF/Share 2.2488
- PFCF 8.7678
- PE 11.5217
- Debt/Assets 0.0026
- DivYield 0
- ROE 0.2747
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 2
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CPRX | Robert W. Baird | -- | Outperform | -- | $28 | Feb. 4, 2025 |
News
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Jeffrey Del Carmen - Executive VP & Chief Commercial Officer Michael W. Kalb - Executive VP, Treasurer & CFO Richard John Daly - President, CEO & Director William T.
Read More
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Read More
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Rising Cash Flows Make These 4 Stocks Worth Choosing Now
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
CPRX, STKL, GAMB and ORN are gaining attention as rising cash flows signal strength, flexibility and growth potential.
Read More
Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Read More
CPRX or STVN: Which Is the Better Value Stock Right Now?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Catalyst (CPRX) Loses 12.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here we present four stocks, GLDD, TILE, CPRX and STRL, with solid net profit margins that can contribute to making a strong portfolio.
Read More
4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here we present four stocks, GLDD, TILE, CPRX and STRL, with solid net profit margins that can contribute to making a strong portfolio.
Read More
Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run?
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
What Makes Catalyst Pharmaceutical (CPRX) a Strong Momentum Stock: Buy Now?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
CPRX or NBIX: Which Is the Better Value Stock Right Now?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more attractive to value investors?
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Does Catalyst (CPRX) Have the Potential to Rally 36.22% as Wall Street Analysts Expect?
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Catalyst (CPRX) Is a Great Choice for 'Trend' Investors, Here's Why
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
About Catalyst Pharmaceuticals, Inc. (CPRX)
- IPO Date 2006-11-08
- Website https://www.catalystpharma.com
- Industry Biotechnology
- CEO Richard John Daly
- Employees 181